Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
- PMID: 20079691
- DOI: 10.1016/S1470-2045(10)70006-1
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
Abstract
Background: The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A.
Methods: 1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 and TOP2A amplification and deletion, HER1-3 and Ki67 expression, and duplication of chromosome 17 centromere enumeration probe (Ch17CEP). Log-rank analyses identified factors affecting relapse-free and overall survival, and regression models tested independent prognostic effect of markers, with adjustment for known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by treatment interactions for relapse-free and overall survival.
Findings: 1762 patients were analysed. 21% of tumours (n=367) were HER2 amplified, 10% were TOP2A amplified (n=169), 11% showed TOP2A deleted (n=191), 23% showed Ch17CEP duplication (n=406), and 61% had high (>13.0%) Ki67 (n=1136). In univariate analyses, only HER2 amplification and TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1.59, 95% CI 1.32-1.92, p<0.0001; and 1.52, 1.20-1.92, p=0.0006, respectively) and overall survival (1.79, 1.47-2.19, p<0.0001; and 1.62, 1.26-2.08, p=0.0002 respectively). We detected no significant interaction with anthracycline benefit for Ki67, HER2, HER1-3, or TOP2A. By contrast, in multivariate analyses, Ch17CEP duplication was associated with significant improvements in both relapse-free (HR 0.92, 95% CI 0.72-1.18 for tumours with normal Ch17CEP vs 0.52, 0.34-0.81 for tumours with abnormal Ch17CEP; p for interaction=0.004) and overall survival (0.94, 0.72-1.24 vs 0.57, 0.36-0.92; p for interaction=0.02) with anthracycline use.
Interpretation: In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication. In view of the location of HER2/TOP2A on chromosome 17, Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting benefit from anthracyclines.
Funding: Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group.
Copyright 2010 Elsevier Ltd. All rights reserved.
Comment in
-
Doubling back on centromere 17 in early breast cancer.Lancet Oncol. 2010 Mar;11(3):216-7. doi: 10.1016/S1470-2045(10)70020-6. Lancet Oncol. 2010. PMID: 20202603 No abstract available.
Similar articles
-
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12. Lancet Oncol. 2011. PMID: 21917518
-
Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2. J Clin Oncol. 2008. PMID: 18768436 Clinical Trial.
-
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.J Clin Oncol. 2015 May 20;33(15):1680-7. doi: 10.1200/JCO.2013.54.7869. Epub 2015 Apr 20. J Clin Oncol. 2015. PMID: 25897160
-
Adjuvant chemotherapy in early breast cancer.Dan Med J. 2016 May;63(5):B5222. Dan Med J. 2016. PMID: 27127018 Review.
-
Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. doi: 10.5507/bp.2009.002. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009. PMID: 19365520 Review.
Cited by
-
Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B Breast Cancer: A Pilot Study.Int J Mol Sci. 2024 Apr 19;25(8):4478. doi: 10.3390/ijms25084478. Int J Mol Sci. 2024. PMID: 38674062 Free PMC article.
-
Disentangling the roles of aneuploidy, chromosomal instability and tumour heterogeneity in developing resistance to cancer therapies.Chromosome Res. 2023 Sep 18;31(4):28. doi: 10.1007/s10577-023-09737-5. Chromosome Res. 2023. PMID: 37721639 Free PMC article. Review.
-
The progress in our understanding of CIN in breast cancer research.Front Oncol. 2023 Feb 16;13:1067735. doi: 10.3389/fonc.2023.1067735. eCollection 2023. Front Oncol. 2023. PMID: 36874134 Free PMC article. Review.
-
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction.Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2209856120. doi: 10.1073/pnas.2209856120. Epub 2022 Dec 27. Proc Natl Acad Sci U S A. 2023. PMID: 36574653 Free PMC article.
-
The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.Histopathology. 2022 Oct;81(4):511-519. doi: 10.1111/his.14728. Epub 2022 Aug 8. Histopathology. 2022. PMID: 35879836 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous